冠心病患者血清晚期糖基化终产物N^ε-羧甲基赖氨酸含量的变化  

Changes in serum concentration of the advanced glycosylation end product N epsilon (carboxymethyl) lysine in patients with coronary heart diseases

作　　者：许顶立[1] 刘艳玲[1] 孟素荣[1] 翁昌鸿[1] 刘志强[2] 刘伊丽[1] 

机构地区：[1]第一军医大学南方医院心脏内科,广东广州510515 [2]第一军医大学南方医院肾脏内科,广东广州510515

出　　处：《中华老年心脑血管病杂志》2000年第3期161-163,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的　观察冠心病患者血清晚期糖基化终产物 (AGE)Nε 羧甲基赖氨酸 (CML)的水平。方法　采用抗戚蓝蛋白晚期糖基化终产物 (KLH AGE)抗体竞争ELISA法 ,对 33例冠心病患者、14例单纯高血压患者及 38名正常人血清中CML进行定量观察。结果　 33例冠心病患者血清中均测得CML ,正常对照组中仅 3名血清CML含量 >0 .1mg/L ,两组比较差异有极显著性意义 (P <0 .0 0 1)。合并高血压的冠心病患者血清CML水平为 (0 .92± 0 .6 1)mg/L ,较单纯高血压 [(0 .2 3± 0 .16 )mg/L]或单纯冠心病 [(0 .44± 0 .47)mg/L]患者明显增高 (P <0 .0 1,P <0 .0 5 )。不合并糖尿病的冠心病患者和合并糖尿病的冠心病患者血清CML水平无显著差异。结论　冠心病患者血清CML水平明显增高 ,提示机体内晚期糖基化终产物的产生在冠状动脉粥样硬化的形成机制中可能起一定的作用。血清CML含量可作为冠心病患者晚期糖基化反应水平的生物学指标。Objective To investigate the serum concentration of N ε carboxymethyl lysine(CML),an advanced glycosylation end product (AGE),in patients with coronary heart disease (CHD).Methods Competitive ELISA using the antibody specific for KLH AGE was used to examine serum levels of CML in 33 cases of CHD,38 health subjects and 14 cases of hypertension.Results CML was detectable (>0.1 mg/L) in 100% of CHD patients as compared with 7.9% in age matched normal subjects (P<0.001).Plasma levels of CML were elevated in the hypertensive CHD patients[(0.92±0.61) mg/L] as compared with hypertension [(0.23±0.16) mg/L]or normotensive CHD [(0.44±0.47) mg/L] patients (P<0.01 and P<0.05).There was no difference in serum concentration of CML between diabetic and non diabetic CHD patients.Conclusion The presence of CML in serum suggests a potential link between the pathogenesis of atherosclerosis and the accumulation of AGE in CHD patients.CML may be used as a biomarker of advanced glycosylative reaction in CHD patients.

关 键 词：冠状动脉疾病 冠状动脉硬化 晚期糖基化终产物 N^ε-羧甲基赖氨酸 

分 类 号：R541.4[医药卫生—心血管疾病]